Human leukocyte antigen associations in postural tachycardia syndrome

Yong-Won Shin1,a, Jangsup Moon1,2,a, Tae-Joon Kim1,3, Do-Yong Kim1, Hyeyeon Chang1, Jin-Sun Jun2, Soon-Tae Lee1, Keun-Hwa Jung1, Kyung-Il Park4, Ki-Young Jung1, Manho Kim1, Sang Kun Lee1 & Kon Chu1

1Department of Neurology, Laboratory for Neurotherapeutics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea
2Department of Neurosurgery, Seoul National University Hospital, Seoul, South Korea
3Department of Neurology, Ajou University School of Medicine, Suwon, South Korea
4Department of Neurology, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, South Korea

Correspondence
Kon Chu, Department of Neurology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. Tel.: +82-2-2072-1878; Fax: + 82-2-2072-7424; E-mail: stemcell.snu@gmail.com

Funding Information
This work was supported by SK Plasma (0620180850, 0620164080) and by the National Research Foundation of Korea (NRF) grant funded by the (MSIT) (NRF-2016R1C1B2016275).

Received: 7 December 2018; Revised: 28 February 2019; Accepted: 1 March 2019

Annals of Clinical and Translational Neurology 2019; 6(5): 962–967
doi: 10.1002/acn3.766

Abstract
Associations between human leukocyte antigen (HLA) and postural orthostatic tachycardia syndrome (POTS) have not been investigated. We included patients diagnosed with POTS and showing orthostatic heart rate increases ≥ 50 during orthostatic vital sign measurement or experiencing syncope/near-syncope while standing (prominent POTS; n = 17). DQB1*06:09 was present in seven (41%) patients, a significantly higher percentage than in healthy Koreans (7%; odds ratio [OR] 8.7, 95% confidence interval [CI] 3.1–24.3, corrected P = 3.2 × 10−4) and epilepsy controls (8%; OR 7.9, 95% CI 2.7–23.5, corrected P = 3.2 × 10−4). Six (35.3%) carried the A*33:03-B*58:01-C*03:02-DRB1*13:02-DQB1*06:09 haplotype. The results signify an autoimmune etiology in prominent POTS.

Introduction
Postural tachycardia syndrome (POTS) is a form of dysautonomia that is characterized by excessive orthostatic tachycardia and the presence of complex symptoms, including orthostatic intolerance.1 Although POTS is an underrecognized disorder and its clinical significance is increasing, the pathophysiology of POTS remains largely unknown. Recently, an autoimmune basis of POTS was suggested, and autoantibodies against adrenergic receptors (ARs), the angiotensin II type 1 receptor (AT1R), and acetylcholine receptors (AchRs) have been reported in POTS patients.2–6

Antigen-presenting cells present small processed peptide sequences from antigen by major histocompatibility complex (MHC) proteins. Variability of HLA alleles can allow for differences in the presentation of peptide ligand by MHCs, which is thought to contribute to aberrant T-cell activation and autoimmunity. In fact, several autoimmune diseases are known to have associations with specific human leukocyte antigen (HLA) alleles.7 Altered HLA allele frequencies in POTS could strongly suggest autoimmunity in POTS pathogenesis. However, the association between HLA and POTS has not yet been investigated.

In this study, we aimed to identify the association between HLA and POTS and investigate the clinical characteristics of patients with POTS in association with HLA.
**Method**

**Study subjects**

We enrolled adult patients with prominent POTS who visited the Seoul National University Hospital (SNUH) for dizziness or loss of consciousness (LOC), and were subsequently diagnosed with POTS between April 2014 and August 2015. For the diagnosis of POTS, we checked blood pressure and heart rate at supine rest and 0, 1, 3, 5, and 10 min after standing. Two consecutive tests were conducted, usually in the afternoon and early the next morning, to increase the sensitivity.8 We chose the orthostatic vital sign test for the diagnosis because active standing is more readily performed early in the morning, can better reflect physiologic conditions compared to head-up tilt testing, and is recommended as an initial evaluation measure.9,10 Patients who showed a heart rate (HR) increase ≥30 (HR ≥ 40 for age ≤ 19) within 10 min after standing, experienced orthostatic intolerance symptoms, and had no clear cause to explain tachycardia, such as acute blood loss, prolonged bed rest, hyperthyroidism, or tachycardia-promoting medication were initially diagnosed with POTS. To select patients with prominent POTS, only the patients who showed an increase in heart rate ≥50/min or syncpe/near-syncpe while standing were included. For patients with a history of LOC, epilepsy was additionally ruled out with overnight video-EEG monitoring. The study was approved by the institutional review board of SNUH, and informed written consent was obtained from all patients.

**HLA genotyping and antibody testing**

Four-digit high-resolution HLA genotyping of five HLA loci (HLA-A, B, C, DRB1, DQB1) was performed using direct DNA sequence analysis according to an established protocol (Biowithus, Seoul, South Korea) as described previously.11,12 Antibody testing was additionally performed for these patients to check whether autoimmune pathogenesis was detected. Serum IgG against human z1-adrenergic receptor (z1AR), b1AR, and nicotinic acetylcholine receptor (N-AChR) antibody was measured by an enzyme-linked immunosorbent assay (ELISA) kit (Cusabio, Wuhan, China) and against z2AR and b2AR by another ELISA kit (CellTrend GmbH, Luckenwalde, Germany).

**Data collection**

Demographic and clinical data were collected. For the 16 patients who were enrolled in our previous prospective study designed to evaluate the medical response in POTS patients,13 orthostatic intolerance symptoms were evaluated using the orthostatic intolerance questionnaire (OIQ),14 along with the degree of depression using the Beck depression inventory-II (BDI-II),15 and health-related quality of life using a 36-item short-form health survey (SF-36)16 at baseline and at 1 and 3 months after treatment for comprehensive evaluation of symptoms and outcome.1 Baseline catecholamines levels including norepinephrine, epinephrine, and dopamine were also checked and collected for the analysis.

### Table 1. Clinical characteristics of the patients.

| Age       | 23 (15–43) |
|-----------|------------|
| Sex (M:F) | 5:12       |
| Height, cm| 165.7 (134.4–185.1) |
| Weight, kg| 53.25 (43.7–102.9) |
| BMI, kg/m²| 20.45 (16.86–35.71) |
| Vaccinated for HPV | 6 (50)% |
| Supine¹  |
| Systolic BP, mmHg | 106 (94.5–124) |
| Diastolic BP, mmHg | 62.5 (52.5–72) |
| Heart rate, bpm | 61.5 (50–82) |
| Standing (immediate)² |
| Systolic BP, mmHg | 106.5 (94.5–128.5) |
| Diastolic BP, mmHg | 64.5 (55–74) |
| Heart rate, bpm | 94 (78.5–124) |
| Maximal heart rate increase | 57 (30–73) |
| Experience of syncpe/presyncpe while standing³ |
| Syncpe/presyncpe | 11 (64.7) |
| Baseline serum catecholamines |
| Norepinephrine, pg/mL | 123.1 (29.9–358.8) |
| Epinephrine, pg/mL | 35 (1–88) |
| Dopamine, pg/mL | 28.4 (3.1–63.2) |
| Questionnaire scores (initial) |
| OIQ | 15 (0–39) |
| BDI-II | 11.5 (3–28) |
| PCS | 49.4 (19.2–58.6) |
| MCS | 47.6 (25.6–62.7) |
| Treatment |
| Bisoprolol | 4 (23.5) |
| Bisoprolol and pyridostigmine | 4 (23.5) |
| Bisoprolol and pyridostigmine | 5 (29.4) |
| Propranolol | 4 (23.5) |
| Additional IVIg for relapse | 2 (11.8) |

Data are expressed as median (range) or N (%).

BMI, body mass index; HPV, human papillomavirus; BP, blood pressure; OIQ, orthostatic intolerance questionnaire; BDI-II, Beck depression inventory-II; PCS, physical component summary score of short-form 36 health survey questionnaire; MCS, mental component summary score of short-form 36 health survey questionnaire.

¹Percentage in the female population.

²Mean value of the results of two orthostatic vital sign measurements.

³Ten of the patients reproduced the attack during orthostatic vital sign measurement.
**Multiple sequence alignment and HLA peptide binding prediction**

Protein sequences of z1AR, z2AR, β1AR, β2AR, and AT1R (Uniprot accession numbers P35348, P08913, P08588, P07550, and P30556, respectively) were aligned using a multiple sequence alignment tool (Clustal Omega).17 NetMH-CIIPan-3.218 was used to predict the binding affinity of HLA class II peptides to all possible epitopes with peptide lengths of 15 from each protein. The percentile rank of each epitope was determined by comparing its predicted score against the scores of 200,000 random natural peptides and rank values (%) <3 were considered to have strong affinity.

**Statistical analysis**

For the statistical analysis, we used HLA genotypes of 485 Korean individuals from the general population19 and previously obtained data from 210 epilepsy patients11-12,20 as control groups. We used two control groups to compensate for the small sample size and other possible confounding conditions such as age, sex, and comorbidities that may influence the results.

Odds ratios with 95% confidence intervals were calculated for each HLA type. The association of specific HLA types with POTS was performed using Fisher’s exact test. Correction for multiple testing was performed using the Bonferroni method, that is, multiplying the P values by the total number of detected alleles at each HLA locus. Haplotypes of the control groups were estimated using Arlequin software (version 3.5.2.2)21 as previously described.20 Fisher’s exact test or the Wilcoxon rank-sum test was used as appropriate for between-group comparisons. Statistical analyses were performed using SPSS version 18 (SPSS Inc., Chicago, IL), and the level of significance was set at 0.05.

**Results**

A total of 153 patients with POTS were screened for eligibility in our previous study.13 Among them, 24 subjects fulfilled our criteria for prominent POTS, and 17 of those whose blood samples were stored underwent HLA genotyping. One patient did not return to the clinic after the initial evaluation while the remaining 16 patients underwent follow-up evaluation for treatment response. The clinical characteristics of the patients are summarized in Table 1. In four-digit HLA genotyping, DQB1*06:09 was more prevalent (41%) in the POTS group than in either the epilepsy control group or the healthy control group (Table 2). Six of 17 patients (35.3%) carried the A*13:02-DQB1-06:09 haplotype, which was also significantly more frequent than in the epilepsy and healthy control populations (odds ratio [OR] 8.3 and 8.5, respectively). All 17 patients had antibodies to β2AR, with

| HLA allele or haplotype | POTS | Epilepsy controls | Healthy controls | POTS versus epilepsy controls | POTS versus healthy controls |
|-------------------------|------|-------------------|------------------|------------------------------|----------------------------|
| **Total (n=17)**        |      |                   |                  |                              |                            |
| DQB1*06:09              | 7/17 (41%) | 17/210 (8%) | 36/485 (7%) | 7.9 (2.7–23.5) | 8.9 x 10^-3 |
| C*03:02                 | 8/17 (47%) | 32/210 (15%) | 71/485 (15%) | 4.9 (1.8–13.8) | 0.075 |
| DRB1*13:02              | 7/17 (41%) | 28/210 (13%) | 83/485 (17%) | 4.6 (1.6–12.9) | 0.23  |
| B*58:01                 | 7/17 (41%) | 31/210 (15%) | 59/485 (12%) | 4.1 (1.4–11.4) | 0.51 |
| A*33:03                 | 7/17 (41%) | 56/210 (27%) | 140/485 (29%) | 1.9 (0.7–5.3) | >0.99 |
| Haplotype#1*            | 7/17 (41%) | 16/210 (8%) | 32/485 (7%) | 8.5 (2.8–25.3) | 2.6 x 10^-3 |
| Haplotype#2*            | 6/17 (35%) | 13/210 (6%) | 29/485 (6%) | 8.3 (2.6–25.9) | 6.4 x 10^-3 |
| **Patients with antibodies to both 2AR and 2AR (n=13)** |      |                   |                  |                              |                            |
| DQB1*06:09              | 7/13 (54%) | 17/210 (8%) | 36/485 (7%) | 13.2 (4.0–43.9) | 1.2 x 10^-3 |
| C*03:02                 | 8/13 (62%) | 32/210 (15%) | 71/485 (15%) | 8.9 (2.7–28.9) | 8.0 x 10^-3 |
| DRB1*13:02              | 7/13 (54%) | 28/210 (13%) | 83/485 (17%) | 7.6 (2.4–24.2) | 0.057 |
| B*58:01                 | 7/13 (54%) | 31/210 (15%) | 59/485 (12%) | 6.7 (2.1–21.4) | 0.086 |
| A*33:03                 | 7/13 (54%) | 56/210 (27%) | 140/485 (29%) | 3.2 (1.0–10.0) | >0.99 |
| Haplotype#1*            | 7/13 (54%) | 16/210 (8%) | 32/485 (7%) | 14.1 (4.2–47.1) | 3.4 x 10^-4 |
| Haplotype#2*            | 6/13 (46%) | 13/210 (6%) | 29/485 (6%) | 13.0 (3.8–44.3) | 1.2 x 10^-3 |

Bold text indicates a statistically significant difference.

For haplotype comparisons, the P values were corrected by a factor of 6, considering four combinations and two subgroups. The P values were the results of correction using the Bonferroni’s method for multiple comparisons. For the correction, P values were multiplied by the number of detected alleles for each HLA locus.

*Haplotype#1 = HLA-C*03:02-B*58:01-DRB1*13:02-DQB1*06:09; Haplotype#2 = HLA-A-33:03- C*03:02-B*58:01-DRB1*13:02-DQB1*06:09.
also having z2AR antibodies. Subgroup analysis of the patients whose sera showed positivity for both α and β ADR antibodies indicated that a stronger association was observed for approximately half of the patients having DQB1*06:09 (OR 13.2 and 14.6, compared to epilepsy controls and healthy controls, respectively).

There were no differences in age, sex, HPV vaccination status, maximum heart rate increase, baseline serum catecholamine level or scores of OIQ, BDI-II, and SF-36 physical and mental components between the patients with and without the DQB1*06:09 allele (Table S1).

Epitopes with the highest predicted affinity to the DQA1*0101:DQB1*0609 alleles

Epitopes of β2AR and AT1R with strong affinity to the DQA1*0101:DQB1*0609 alleles and located nearest to the epitopes of α1AR, α2AR and β1AR highlighted in yellow
performed at 1 \((n = 16)\) and 3 months \((n = 13)\) also showed no difference. At last follow-up (median 12 month, range 0–48 month), nine patients reported no or only minor symptoms without relapse. Two patients received intravenous immunoglobulin (IVIg) at the recurrence of orthostatic intolerance. One showed complete resolution of symptoms 1 month after a 5-day IVIg infusion (400 mg/kg for 5 days). The other showed a delayed response with amelioration of symptoms 5 months after IVIg treatment (5-day IVIg infusion followed by 5 replacements at 400 mg/kg per month).

Epitope prediction using NetMHCIIPan-3.2\(^{18}\) showed that epitopes of \(\alpha_1/2\)AR and \(\beta_1\)AR with the highest predicted affinity to the DQA1*01:02-DQB1*06:09 alleles are found in similar locations in highly homogenous regions (Fig. 1). \(\beta_2\)AR and AT1R also had epitopes predicted to have strong affinity in the same region, although epitopes with the highest predicted affinity are in different locations. These findings could partly explain multiple target antigens in POTS by molecular mimicry.

**Discussion**

There is a remarkable association of prominent POTS with the DQB1*06:09 allele. This report is the first to investigate the HLA association with POTS. All patients with prominent POTS had autoantibodies to \(\beta_2\)AR, which suggests antibody-mediated pathophysiology in these patients. Two of our patients responded to immunotherapy after symptom recurrence, suggesting the feasibility of immunotherapy in prominent POTS.

An autoimmune etiology in POTS is suggested by a number of clinical features (e.g., female predominance, preceding viral illness, prior vaccination history, and coexistence of other autoimmune conditions) along with autoantibodies.\(^6\) Antibody-mediated autoimmune disorders usually have an HLA class II association.\(^7\) While lacking in vivo animal model confirmation, the strong association found in the HLA-DQ locus, along with the functionality of the autoantibodies demonstrated experimentally,\(^2,3\) supports the hypothesis that autoimmune POTS is antibody-mediated. Immunotherapeutic agents, including IVIg, may be considered for the treatment of prominent POTS in this regard. Although most clinical features of the study population were not different according to the HLA-DQ genotype, marginal differences in heart rate on standing (Table S1) suggest the potential of different clinical manifestations that might be revealed by a larger population study.

Several etiologies are suggested in patients with POTS; however, a considerable number of patients with POTS seem to have antibodies to one or more of the ARs according to recent studies.\(^2,3\) Among the autoantibodies reported in POTS, approximately half of the patients had autoantibodies to \(\beta_2\)AR in previous studies.\(^2,3\) All patients had antibodies to \(\beta_2\)AR in the current study. Applying more strict criteria may have resulted in increased etiological homogeneity in our patient pool, and the results drawn from prominent POTS patients may be different from the entire POTS population.

There are limitations to this study. First, the small number of patients and ethnic homogeneity limited generalization, and thus, our results need future validation. However, comparison of HLA types within one ethnic population could lower the chance of spurious associations. Therefore, ethnic homogeneity could also be a strength especially in the setting of our small sample size. Second, the proportion of antibodies detected from the patients was different from those detected in previous studies, which might have arisen from the different methods used for antibody detection. Antibodies to \(\alpha_1\)AR and \(\beta_1\)AR, which are known to be detected in POTS by cell-based assays,\(^2,3\) were not detected by ELISA, which also suggests that antibodies to \(\alpha_1\)AR and \(\beta_1\)AR respond to conformational epitopes. Third, as we only investigated selected patients with prominent POTS, the results may not be generalizable to all patients diagnosed with POTS by heart rate cut-off of 30. For increased generalizability, the HLA association needs to be re-evaluated in all POTS patients meeting the clinical diagnostic criteria.

Autoimmune etiology is gaining increasing attention. The HLA association revealed in this study further emphasizes autoimmunity in the pathogenesis of POTS. The severity and prognostic association of POTS with the
HLA subtype need future investigation with a larger population. Future well-designed trials investigating the benefit of immunotherapy in POTS are also warranted.

**Acknowledgments**

This work was supported by SK Plasma (0620180850, 0620164080) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1C1B2016275).

**Author Contributions**

J.M. and K.C. designed the study. Y.W.S., J.M., T.J.K., D.Y.K., and J.S.J. collected the data. J.M. performed the HLA typing and autoantibody testing. Y.W.S. and J.M. performed the statistical analysis and drafted the initial manuscript. All authors contributed to data acquisition, final analysis, and revision of the manuscript.

**Conflict of Interest**

The authors declare no conflict of interest.

**References**

1. Moon J, Kim DY, Byun JI, et al. Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome. Health Qual Life Outcomes 2016;14:144.

2. Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc 2014;3:e000755.

3. Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace 2017;19:1211–1219.

4. Yu X, Li H, Murphy TA, et al. Angiotensin II type 1 receptor autoantibodies in postural tachycardia syndrome. J Am Heart Assoc 2018;7:e008351.

5. Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343:847–855.

6. Vernino S, Stiles LE. Autoimmunity in postural orthostatic tachycardia syndrome: current understanding. Auton Neurosci 2018;215:78–82.

7. Sollid LM, Pos W, Wucherpfennig KW. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr Opin Immunol 2014;31:24–30.

8. Moon J, Lee HS, Byun JI, et al. The complexity of diagnosing postural orthostatic tachycardia syndrome: influence of the diurnal variability. J Am Soc Hypertens 2016;10:263–270.

9. Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome - diagnosis, physiology, and prognosis. Auton Neurosci 2018;215:3–11.

10. Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015;12:e41–e63.

11. Moon J, Park HK, Chu K, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia 2015;56:e161–e167.

12. Moon J, Kim TJ, Lim JA, et al. HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Epilepsia 2016;57:1879–1886.

13. Moon J, Kim DY, Lee WJ, et al. Efficacy of propranolol, bisoprolol, and pyridostigmine for postural tachycardia syndrome: a randomized clinical trial. Neurotherapeutics 2018;15:785–795.

14. Winker R, Barth A, Dorner W, et al. Diagnostic management of orthostatic intolerance in the workplace. Int Arch Occup Environ Health 2003;76:143–150.

15. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588–597.

16. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437–1440.

17. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:539.

18. Jensen KK, Andrreatta M, Marcattili P, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology 2018;154:394–406.

19. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005;65:437–447.

20. Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol 2017;81:183–192.

21. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 2010;10:564–567.

22. Yang JH, Sohn YH, Ko SY, et al. Anthropological analysis of Koreans using HLA class II diversity among East Asians. Tissue Antigens 2010;76:282–288.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1.** Comparison of clinical characteristics of patients with or without the DQB1*06:09 allele.